Grant
$100k
Melbourne biotech ImmunoBiota progresses $5m seed raise for world-first oral Type 1 diabetes therapy
Melbourne biotech ImmunoBiota courts investors for its still-open seed round around an oral Type 1 diabetes therapy; its recent Diabetes Australia award is recorded, while the flagged Series A and listing remain plans.